Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Cancers (Basel)
2018 May 05;105:. doi: 10.3390/cancers10050133.
Show Gene links
Show Anatomy links
Translation Control by p53.
Kasteri J
,
Das D
,
Zhong X
,
Persaud L
,
Francis A
,
Muharam H
,
Sauane M
.
???displayArticle.abstract???
The translation of mRNAs plays a critical role in the regulation of gene expression and therefore, in the regulation of cell proliferation, differentiation and apoptosis. Unrestricted initiation of translation causes malignant transformation and plays a key role in the maintenance and progression of cancers. Translation initiation is regulated by the ternary complex and the eukaryotic initiation factor 4F (eIF4F) complex. The p53 tumor suppressor protein is the most well studied mammalian transcription factor that mediates a variety of anti-proliferative processes. Post-transcriptional mechanisms of gene expression in general and those of translation in particular play a major role in shaping the protein composition of the cell. The p53 protein regulates transcription and controls eIF4F, the ternary complex and the synthesis of ribosomal components, including the down-regulation of rRNA genes. In summary, the induction of p53 regulates protein synthesis and translational control to inhibit cell growth.
Aktas,
Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole.
1998, Pubmed
Aktas,
Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole.
1998,
Pubmed
Anger,
Structures of the human and Drosophila 80S ribosome.
2013,
Pubmed
Benzaquen,
Clotrimazole inhibits cell proliferation in vitro and in vivo.
1995,
Pubmed
Bjornsti,
Lost in translation: dysregulation of cap-dependent translation and cancer.
2004,
Pubmed
Brostrom,
Inhibition of translational initiation in eukaryotic cells by calcium ionophore.
1989,
Pubmed
Budanov,
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.
2008,
Pubmed
Budde,
p53 represses ribosomal gene transcription.
1999,
Pubmed
Bywater,
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
2012,
Pubmed
Cairns,
p53 is a general repressor of RNA polymerase III transcription.
1998,
Pubmed
Chen,
Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational control of human p53 mRNA.
2012,
Pubmed
Chesnokov,
p53 inhibits RNA polymerase III-directed transcription in a promoter-dependent manner.
1996,
Pubmed
Chu,
Therapeutic Opportunities in Eukaryotic Translation.
2018,
Pubmed
Constantinou,
Regulation of translation factors eIF4GI and 4E-BP1 during recovery of protein synthesis from inhibition by p53.
2007,
Pubmed
Constantinou,
Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53.
2005,
Pubmed
Cramer,
Structure of eukaryotic RNA polymerases.
2008,
Pubmed
Dever,
Translation Elongation and Recoding in Eukaryotes.
2018,
Pubmed
Gandin,
mTORC1 and CK2 coordinate ternary and eIF4F complex assembly.
2016,
Pubmed
Gentilella,
A liaison between mTOR signaling, ribosome biogenesis and cancer.
2015,
Pubmed
Gibbons,
Concerted copy number variation balances ribosomal DNA dosage in human and mouse genomes.
2015,
Pubmed
Gingras,
Hierarchical phosphorylation of the translation inhibitor 4E-BP1.
2001,
Pubmed
Herrmann,
Association of casein kinase II with immunopurified p53.
1991,
Pubmed
Hinnebusch,
The scanning mechanism of eukaryotic translation initiation.
2014,
Pubmed
Ho,
p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest.
2005,
Pubmed
Horton,
p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation.
2002,
Pubmed
Ingolia,
Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling.
2009,
Pubmed
Jenner,
Crystal structure of the 80S yeast ribosome.
2012,
Pubmed
Kastenhuber,
Putting p53 in Context.
2017,
Pubmed
Kozak,
Structural features in eukaryotic mRNAs that modulate the initiation of translation.
1991,
Pubmed
Li,
Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress.
2007,
Pubmed
Litchfield,
Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.
2003,
Pubmed
Loayza-Puch,
p53 induces transcriptional and translational programs to suppress cell proliferation and growth.
2013,
Pubmed
Loging,
Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
1999,
Pubmed
Malka-Mahieu,
Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.
2017,
Pubmed
Marcel,
p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer.
2013,
Pubmed
Meek,
The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II.
1990,
Pubmed
Nathan,
Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications.
2000,
Pubmed
Pain,
Initiation of protein synthesis in eukaryotic cells.
1996,
Pubmed
Petersson,
The p53 target gene TRIM22 directly or indirectly interacts with the translation initiation factor eIF4E and inhibits the binding of eIF4E to eIF4G.
2012,
Pubmed
Petroulakis,
p53-dependent translational control of senescence and transformation via 4E-BPs.
2009,
Pubmed
Preukschas,
Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
2012,
Pubmed
Prowald,
Regulation of the DNA binding of p53 by its interaction with protein kinase CK2.
1997,
Pubmed
Quin,
Targeting the nucleolus for cancer intervention.
2014,
Pubmed
Rahman,
PKR is not a universal target of tumor suppressor p53 in response to genotoxic stress.
2009,
Pubmed
Robichaud,
Translational control and the cancer cell response to stress.
2017,
Pubmed
Roux,
Signaling Pathways Involved in the Regulation of mRNA Translation.
2018,
Pubmed
Ruzzene,
Addiction to protein kinase CK2: a common denominator of diverse cancer cells?
2010,
Pubmed
Schuster,
Regulation of p53 mediated transactivation by the beta-subunit of protein kinase CK2.
1999,
Pubmed
Schuster,
Wild-type p53 inhibits protein kinase CK2 activity.
2001,
Pubmed
Shen,
Protein synthesis. Rqc2p and 60S ribosomal subunits mediate mRNA-independent elongation of nascent chains.
2015,
Pubmed
Shishova,
High-resolution microscopy of active ribosomal genes and key members of the rRNA processing machinery inside nucleolus-like bodies of fully-grown mouse oocytes.
2015,
Pubmed
Stein,
RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
2002,
Pubmed
Stults,
Genomic architecture and inheritance of human ribosomal RNA gene clusters.
2008,
Pubmed
Sulima,
How Ribosomes Translate Cancer.
2017,
Pubmed
Takagi,
Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin.
2005,
Pubmed
Voigts-Hoffmann,
Structural insights into eukaryotic ribosomes and the initiation of translation.
2012,
Pubmed
Yang,
A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A.
2004,
Pubmed
Zaccara,
p53-directed translational control can shape and expand the universe of p53 target genes.
2014,
Pubmed
Zhai,
Repression of RNA polymerase I transcription by the tumor suppressor p53.
2000,
Pubmed
Zhang,
Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop.
2013,
Pubmed
Zhao,
Inactivation of ribosomal protein S27-like confers radiosensitivity via the Mdm2-p53 and Mdm2-MRN-ATM axes.
2018,
Pubmed
